UNSPSC 51432309: Trimetaphan camsilate or trimethaphan camsylate

This classification denotes a nicotinic antagonist and antihypertensive agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8W556014K9. European Medicines Agency schedules Trimetaphan camsilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11305MIG. Trimetaphan camsilate generally arises in the molecular formula C22H25N2OS.C10H15O4S. The term TRIMETAPHAN CAMSILATE is an International Non-Proprietary Name or INN.

Trimetaphan camsilate or trimethaphan camsylate bears US NLM identifiers UMLS ID C0077158 and NCI Concept Code C66639. SMILES: [S]12C(C3N(C(=O)N(C3C1)Cc1ccccc1)Cc1ccccc1)CCC2.S(=O)(=O)(O)CC12C(C(CC1)CC2=O)(C)C.

UNSPSC 51432309 Trimetaphan camsilate or trimethaphan camsylate is a Commodity code representing a specific injectable vasodilator medication used in emergency and acute-care settings. State and local governments procure this drug primarily through fire rescue services, emergency medical systems, and health agency pharmacy programs that stock advanced life support medications for paramedic and emergency protocols. The code covers acquisition of the pharmaceutical itself—typically in vial or injection form with specified strength and volume—rather than administration services or equipment. Issuing bodies include municipal fire departments and their parent purchasing offices, state health and human services agencies managing Medicaid or employee pharmacy benefits, and multistate cooperative purchasing alliances that aggregate demand across member jurisdictions to negotiate manufacturer pricing and distribution terms.

Recent solicitation activity shows Tampa Fire Rescue's procurement through the City of Tampa Purchasing Department (IFB 26P00188, closed April 8, 2026) for advanced life support medications including multiple injectable agents, with a one-year contract valued at $40,000 and renewal options; the Texas Health and Human Services Commission's RFI (HHS0017013, March 2026) exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon. Geographic activity concentrates in Texas, Florida, and the Upper Midwest, with cooperative purchasing vehicles like MMCAP expanding reach across multiple states. Vendors must maintain cGMP and DSCSA compliance, arrange third-party wholesaler distribution relationships, meet nine-month-to-one-year minimum shelf-life requirements, and provide Safety Data Sheets and accessibility documentation per federal standards.